Cargando…
Author response to “lack of benefit from low dose computed tomography in screening for lung cancer”
We explain to Dr. Benjamin (corresponding author) about why low-dose computed tomography reduce lung cancer mortality without significantly reducing all-cause mortality. We also conduct an up-to-date meta-analysis to evaluate low-dose computed tomography clinical effectiveness compared with usual ca...
Autores principales: | Huang, Kai-Lin, Wang, Shih-Yuan, Lu, Wan-Chen, Chang, Ya-Hui, Su, Jian, Lu, Yen-Ta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450698/ https://www.ncbi.nlm.nih.gov/pubmed/32847562 http://dx.doi.org/10.1186/s12890-020-01247-y |
Ejemplares similares
-
Lack of benefit from low dose computed tomography in screening for lung cancer - comment on paper by Huang K-L et al.
por: Benjamin, Don
Publicado: (2020) -
Effects of low-dose computed tomography on lung cancer screening: a systematic review, meta-analysis, and trial sequential analysis
por: Huang, Kai-Lin, et al.
Publicado: (2019) -
Understanding the lung cancer mortality reductions produced by low-dose CT screening—Authors’ reply
por: Duffy, Stephen W., et al.
Publicado: (2021) -
What is the balance of benefits and harms for lung cancer screening with low-dose computed tomography?
por: Bradley, Stephen H, et al.
Publicado: (2021) -
Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)